Skip to main content
Premium Trial:

Request an Annual Quote

Shares in Ciphergen Up 5 Percent on Sanofi-Aventis Deal

NEW YORK, Feb. 7 (GenomeWeb News) - Shares of Ciphergen were trading up $.08, or 5.06 percent, at $1.66 in afternoon trade following news of an alliance with Sanofi-Aventis.


As GenomeWeb News reported this morning, Ciphergen said it  extended a deal with Sanofi-Aventis to discover, validate, and identify biomarkers for a pre-clinical oncology drug efficacy study.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.